Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.49M | 36.31M | 37.32M | 36.34M | 36.23M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.49M | 36.31M | 37.32M | 36.34M | 36.23M |
| Cost of Revenue | 23.79M | 24.05M | 25.00M | 24.23M | 25.19M |
| Gross Profit | 11.71M | 12.26M | 12.32M | 12.11M | 11.05M |
| SG&A Expenses | 15.03M | 15.33M | 15.75M | 16.20M | 15.16M |
| Depreciation & Amortization | 344.10K | 332.00K | 298.50K | 267.30K | 245.70K |
| Other Operating Expenses | 488.80K | 469.30K | 451.60K | 388.20K | 421.30K |
| Total Operating Expenses | 40.07M | 40.78M | 42.18M | 41.77M | 41.94M |
| Operating Income | -4.58M | -4.48M | -4.86M | -5.43M | -5.71M |
| Income Before Tax | -5.98M | -5.95M | -6.51M | -6.47M | -5.33M |
| Income Tax Expenses | 61.80K | 21.60K | -515.50K | -162.90K | -297.40K |
| Earnings from Continuing Operations | -6.04 | -5.98 | -5.99 | -6.31 | -5.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.04M | -5.98M | -5.99M | -6.31M | -5.03M |
| EBIT | -4.58M | -4.48M | -4.86M | -5.43M | -5.71M |
| EBITDA | -4.23M | -4.15M | -4.56M | -5.17M | -5.46M |
| EPS Basic | -13.85 | -15.68 | -21.87 | -30.13 | -47.82 |
| Normalized Basic EPS | -5.95 | -7.18 | -12.22 | -16.86 | -15.46 |
| EPS Diluted | -13.85 | -15.68 | -21.87 | -30.13 | -47.82 |
| Normalized Diluted EPS | -5.95 | -7.18 | -12.22 | -16.86 | -15.46 |
| Average Basic Shares Outstanding | 15.79M | 15.57M | 12.59M | 8.98M | 4.03M |
| Average Diluted Shares Outstanding | 15.79M | 15.57M | 12.59M | 8.98M | 4.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |